Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363220 · ClinicalTrials.gov registry record
Community - Associated Extended-spectrum Beta-lactamases (ESBL)
A clinical trial of Infection and E Coli Infections, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT00363220 is a study of Infection and E Coli Infections that has completed, run by University of Pittsburgh. The registered enrollment target is 100 participants, below the 724-participant average among 41 other Infection trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00363220, a study of Infection and E Coli Infections, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to review patients with E. coli infections at the University of Pittsburgh Medical Center (UPMC) from September 1, 2006 to August 31, 2007 to determine if these infections have arisen in the community rather than in hospitals or nursing homes. The occurrence of such resistant isolates could be devastating if they were associated with bloodstream infection, such as sometimes accompanies a urinary tract infection, since antibiotic resistant E. coli is not suspected in isolates coming from the community. Therefore, the aims of this study are to: 1. Review whether extended-spectrum beta-lactamase (ESBL)-producing organisms (E. coli, Klebsiella species and Proteus species) are hospital-acquired, healthcare-associated, or community-associated. 2. Investigate the prevalence of ESBL-positive E. coli in foodstuffs (beef, poultry, turkey, and pork), as a potential source for ESBL producers in the community. 3. Compare the clonal relationship of the genome and resistance plasmids carried by the ESBL-producing isolates (healthcare-associated, community-associated, and of animal origin) and study the associations of ESBL-mediated resistance with resistance to other classes of antimicrobials.
Conditions Studied
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2006-08 |
| Est. Completion | 2015-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00363220
The ClinicalTrials.gov registry entry for NCT00363220 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 724-participant average among 41 other Infection trials with a reported enrollment target (86% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Infection appearing as the primary indexed condition, and to 0 interventions.
NCT00363220 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00363220 about?
NCT00363220 is a clinical study titled "Community - Associated Extended-spectrum Beta-lactamases (ESBL)". The purpose of this study is to review patients with E. coli infections at the University of Pittsburgh Medical Center (UPMC) from September 1, 2006 to August 31, 2007 to determine if these infections have arisen in the community rather than in hospitals or nursing homes. The occurrence of such resi...
What is the current status of trial NCT00363220?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2006-08. Estimated completion is 2015-12.
What conditions does trial NCT00363220 study?
This clinical trial studies the following conditions: Infection, E Coli Infections, Klebsiella Infections, Proteus Infections.
Who is sponsoring clinical trial NCT00363220?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00363220 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Home Hospital for Suddenly Ill Adults
RECRUITING · NA
-
Copper Supplementation in Cirrhosis
RECRUITING · NA
-
Persona Revision Knee System Outcomes
RECRUITING
-
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
RECRUITING · Phase 1
-
Diagnosis and Management of Inflammatory and Infectious Diseases
RECRUITING
-
BLOOM: Pragmatic Feasibility Trial
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.